Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) dropped 5.4% during trading on Monday. The company traded as low as C$1.38 and last traded at C$1.39. Approximately 53,341 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 139,386 shares. The stock had previously closed at C$1.47.
Cardiol Therapeutics Trading Down 2.2%
The firm has a market capitalization of C$173.66 million, a price-to-earnings ratio of -4.00 and a beta of 0.14. The firm’s 50 day moving average is C$1.94 and its 200 day moving average is C$1.82. The company has a quick ratio of 6.84, a current ratio of 6.26 and a debt-to-equity ratio of 0.35.
Cardiol Therapeutics (TSE:CRDL – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported C($0.11) earnings per share (EPS) for the quarter. Equities analysts forecast that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current year.
About Cardiol Therapeutics
Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
Further Reading
- Five stocks we like better than Cardiol Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
